Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

709 Nitric oxide-releasing topical therapeutic agent for atopic dermatitis

2017; Elsevier BV; Volume: 137; Issue: 5 Linguagem: Inglês

10.1016/j.jid.2017.02.732

ISSN

1523-1747

Autores

K. McHale, Joel Gil, SC Davis, Stan Hollenbach, Nathan Stasko,

Tópico(s)

Dermatology and Skin Diseases

Resumo

AD is a pruritic allergic inflammatory skin disease with increasing prevalence among pediatric and adolescent age groups.Current topical treatments are associated with a range of detrimental side effects.Isoprenylcysteine (IPC) small molecules represent a novel class of topically applied non-steroidal anti-inflammatory drugs, whose action is locally restricted.We demonstrate here the use of a novel IPC analog, SIG-1451 for AD in multiple cell-based assays targeting key pro-inflammatory cytokines that drive AD allergic pathogenesis.In human PBMCs, SIG-1451 inhibits IL-4 cytokine release elicited by CD3/CD28 (IC 50 ¼ 20 mM) and abrogates a Ni 2+ -TLR4 response in endothelial cells by reducing IL-6 (IC 50 ¼ 0.02 mM).In NHEKs, SIG-1451 inhibits S. aureus-induced release of TSLP (IC 50 ¼ 3 mM).SIG-1451 activity

Referência(s)